Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal despite its known efficacy in reducing recurrence and mortality. This study aims to investigate factors associated with non-adherence and inform the development of interventions to support women and promote adherence. A questionnaire survey to measure level of adherence, side effects experienced, beliefs about medicine, support received and socio-demographic details was sent to 292 women 2-4 years post breast cancer diagnosis. Differences between non-adherers and adherers to AET were explored, and factors associated with intentional and unintentional non-adherence are reported. Approximately one quarter of respondents, 46 (22%), were non-adherers...
This study aimed to investigate the prevalence of and factors associated with non-adherence to medic...
International audiencePurpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal desp...
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal desp...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women...
Abstract Background Interventions that promote adjuvant endocrine therapy (AET) adherence are critic...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Purpose: To inform intervention development, we measured the modifiable determinants of endocrine th...
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortal...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
This study aimed to investigate the prevalence of and factors associated with non-adherence to medic...
International audiencePurpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal desp...
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal desp...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women...
Abstract Background Interventions that promote adjuvant endocrine therapy (AET) adherence are critic...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Purpose: To inform intervention development, we measured the modifiable determinants of endocrine th...
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortal...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
This study aimed to investigate the prevalence of and factors associated with non-adherence to medic...
International audiencePurpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...